Monte Rosa Therapeutics, Inc. — Form D
Monte Rosa Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-09-29. The offering totals $96.0M, of which $48.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-09-29
- Form: D
- Accession: 0001826457-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $96.0M
- Amount sold: $48.0M
- Remaining: $48.0M
- Investors: 17
- Date of first sale: 2020-09-14
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-376612
Issuer
- Name: Monte Rosa Therapeutics, Inc.
- CIK: 0001826457
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 40 GUEST STREET, BOSTON, MA, 02458
- Phone: 917-363-0113
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Ali Behbahani | Director | Littleton, CO |
| Kim Blackwell | Director | Philadelphia, PA |
| Bradley Bolzon | Director | SAN DIEGO, CA |
| Alexander Mayweg | Director | South San Francisco, CA |
| Markus Warmuth | Director | c/o Ventus Therapeutics U.S.,, MA |
| Markus Warmuth | Executive Officer | c/o Ventus Therapeutics U.S.,, MA |
| Drew Schiff | Director | Boston, MA |
| Chandra P Leo | Director | Boston, MA |
| Christine P Siu | Director | Boston, MA |
| Ajim P Tamboli | Executive Officer | Boston, MA |
Other filings by this issuer (1)
More